stephen silberstein, md, director, jefferson university headache center.
.
fremanezumab has completed phase iii trials and is under review by the fda to prevent migraine and
.
over the years, i�ve talked to reporters who are solidly addicted to obfuscations. like any addict, they have an army of excuses to rationalize their behavior.
.